Epstein-barr virus antibodies and risk of multiple sclerosis

The multiple sclerosis gut microbiota: A systematic review. Mult Scler Relat Disord 37 Body mass index during adolescence, rather than childhood, is critical in determining MS risk. Mult Scler 22 — Rasul T, Frederiksen JL. Novo AM, Batista S. Multiple Sclerosis: Implications of Obesity in Neuroinflammation.

Adv Neurobiol 19 — Immunometabolism 2 :e Trends Mol Med 26 — The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging.

Neural Regener Res 14 — Cureus 11 :e Human inborn errors of immunity to herpes viruses. Curr Opin Immunol 62 — Herpesviridae and novel inhibitors. Antivir Ther 14 — Human Herpesviruses. J Virol 93 2 :e— Cancer Med 6 — RNA families in Epstein-Barr virus. RNA Biol 11 —7. Structural genomics of the Epstein-Barr virus. Acta Crystallogr D Biol Crystallogr 62 — Longnecker R, Neipel F. In: Arvin, et al. Liu F, Zhou ZH. Comparative virion structures of human herpesviruses. Hammerschmidt W.

Curr Top Microbiol Immunol — The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease. Immunol Res 58 — Clin Microbiol Rev 24 — Crawford DH. Biology and disease associations of Epstein-Barr virus. A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells.

Life Sci 65 — Chakravorty A. Sugden B, Johannsen EC. J Virol 93 :e— Chiu YF, Sugden B. Annu Rev Virol 3 — Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation. Adv Virus Res 88 — Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol 17 — Kempkes B, Robertson ES. Epstein-Barr virus latency: current and future perspectives.

Curr Opin Virol 14 — Murata T. Regulation of Epstein-Barr virus reactivation from latency. Microbiol Immunol 58 — Kerr JR. Epstein-Barr virus EBV reactivation and therapeutic inhibitors. J Clin Pathol 72 —8. Kenney SC. Reactivation and lytic replication of EBV. Maintenance and replication during latency. Immune Evasion by Epstein-Barr Virus. Epstein-Barr virus-encoded microRNAs as regulators in host immune responses.

Int J Biol Sci 14 — J Virol 91 :e— Rowe M, Zuo J. Microbes Infect 12 — Middeldorp JM. Latour S, Fischer A. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.

Immunol Rev — Innate immune responses against Epstein Barr virus infection. J Leukoc Biol 94 — Microorganisms 7 J Virol 90 — Blood — PloS Pathog 5 :e J Immunol — Semin Cancer Biol 18 — Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replication. J Virol 81 — The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing.

The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J Virol 76 — Infectious Mononucleosis. J Clin Virol — Farrell PJ. Epstein-Barr Virus and Cancer. Annu Rev Pathol 14 — Primary Epstein-Barr virus infection with and without infectious mononucleosis.

PloS One 14 :e Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach. Pathology 52 — Hydroa vacciniforme: a distinctive form of Epstein-Barr virus-associated T-cell lymphoproliferative disorders.

Eur J Dermatol 29 —8. Front Microbiol 7 Saha A, Robertson ES. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin Cancer Res 17 — Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 1 — Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol Lancet Neurol 15 — B Cells and Autoantibodies in Multiple Sclerosis.

Int J Mol Sci 16 — The role of antibodies in multiple sclerosis. Biochim Biophys Acta — Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.

Natalizumab therapy for multiple sclerosis. Semin Neurol 33 — Shannon-Lowe C, Rowe M. Epstein Barr virus entry; kissing and conjugation.

Scher, Kassandra L. Munger, Alberto Ascherio. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.

Science , DOI: ScienceDaily, 13 January Harvard T. Epstein-Barr virus may be leading cause of multiple sclerosis. Retrieved January 13, from www. McAlpine's Multiple Sclerosis. Edinburgh, Scotland: Churchill-Livingstone; Hafler DA. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J Clin Invest. Google Scholar. T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice.

J Immunol. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. J Exp Med. Cohen JI. Epstein-Barr virus infection. N Engl J Med. Vaughan JH. The Epstein-Barr virus in autoimmunity. Springer Semin Immunopathol.

Multiple sclerosis and Epstein-Barr virus. A case-control study of multiple sclerosis. Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Symptomatic Epstein-Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry. Multiple sclerosis and antecedent infections: a case-control study. Increased risk of multiple sclerosis after late Epstein-Barr virus infection. Mult Scler.

Multiple sclerosis and age at infection with common viruses. Ascherio A, Munch M. Epstein-Barr Virus and multiple sclerosis. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Viral antibody titers: comparison in patients with multiple sclerosis and rheumatoid arthritis.

Arch Neurol. Ubiquitous pathogens: links between infection and autoimmunity in MS? Hepatitis B vaccination and the risk of multiple sclerosis. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. Geographic variation of MS incidence in two prospective studies of US women.

Eur J Cancer. Lennette E, Lennette D. Immune Adherence Hemagglutination. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol. Analysis of Longitudinal Data. Oxford, England: Clarendon Press; Results: The average time between blood collection and MS onset was 4 years.

Similarly strong positive associations between EBV antibodies and risk of MS were already present in samples collected 5 or more years before MS onset.